应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01877 君实生物
已收盘 07-22 16:08:56
12.980
+0.300
+2.37%
最高
13.260
最低
12.560
成交量
41.94万
今开
13.000
昨收
12.680
日振幅
5.52%
总市值
127.94亿
流通市值
28.46亿
总股本
9.86亿
成交额
545.09万
换手率
0.19%
流通股本
2.19亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
北向资金7月18日净买入君实生物-U25.58万股 连续3日增持
自选股智能写手 · 07-19
北向资金7月18日净买入君实生物-U25.58万股 连续3日增持
港股异动 | 君实生物(01877)涨超4% 特瑞普利单抗新适应症上市申请获受理
智通财经网 · 07-18
港股异动 | 君实生物(01877)涨超4% 特瑞普利单抗新适应症上市申请获受理
智通港股早知道 | 两部门再出减税惠企大礼包 华为Pura 70系列手机爆火
智通财经 · 07-18
智通港股早知道 | 两部门再出减税惠企大礼包 华为Pura 70系列手机爆火
君实生物(01877.HK)特瑞普利单抗新适应症上市申请获受理
阿斯达克财经 · 07-18
君实生物(01877.HK)特瑞普利单抗新适应症上市申请获受理
港股公告掘金 | 时代电气预期上半年归母净利约15.07亿元 同比增长30.56%
智通财经 · 07-17
港股公告掘金 | 时代电气预期上半年归母净利约15.07亿元 同比增长30.56%
君实生物(01877):特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的新适应症上市申请获得受理
智通财经 · 07-17
君实生物(01877):特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的新适应症上市申请获得受理
君实生物:特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的新适应症上市申请获得受理
国际金融报 · 07-17
君实生物:特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的新适应症上市申请获得受理
君实生物(01877)下跌5.13%,报12.58元/股
金融界 · 07-16
君实生物(01877)下跌5.13%,报12.58元/股
君实生物盘中异动 下午盘快速跳水5.13%
自选股智能写手 · 07-16
君实生物盘中异动 下午盘快速跳水5.13%
君实生物07月12日获主力加仓239万元 环比增加696.67%
自选股智能写手 · 07-12
君实生物07月12日获主力加仓239万元 环比增加696.67%
君实生物(01877)上涨5.13%,报13.12元/股
金融界 · 07-11
君实生物(01877)上涨5.13%,报13.12元/股
君实生物盘中异动 急速上涨5.12%
自选股智能写手 · 07-11
君实生物盘中异动 急速上涨5.12%
君实生物(01877)股价上升5.128%,现价港币$13.12
阿斯达克财经 · 07-11
君实生物(01877)股价上升5.128%,现价港币$13.12
港股异动 | 生物医药股集体回暖 创新药重磅利好政策落地 下半年板块仍有多重催化
智通财经 · 07-11
港股异动 | 生物医药股集体回暖 创新药重磅利好政策落地 下半年板块仍有多重催化
君实生物(01877)全资子公司苏州众合生物医药科技通过欧盟 GMP 认证
智通财经 · 07-10
君实生物(01877)全资子公司苏州众合生物医药科技通过欧盟 GMP 认证
君实生物(688180.SH):子公司通过欧盟GMP认证
智通财经 · 07-10
君实生物(688180.SH):子公司通过欧盟GMP认证
君实生物(01877.HK)WJ47156片临床试验申请获受理
阿斯达克财经 · 07-10
君实生物(01877.HK)WJ47156片临床试验申请获受理
君实生物(01877):JS125 获得药物临床试验申请受理通知书
智通财经 · 07-09
君实生物(01877):JS125 获得药物临床试验申请受理通知书
港股异动 | 生物医药股全线回落 创新药重磅利好政策落地 机构称新环境下谈判难度增加
智通财经 · 07-08
港股异动 | 生物医药股全线回落 创新药重磅利好政策落地 机构称新环境下谈判难度增加
君实生物-U7月5日获北向资金加仓125.97万股
自选股智能写手 · 07-08
君实生物-U7月5日获北向资金加仓125.97万股
公司概况
公司名称:
君实生物
所属市场:
SEHK
上市日期:
--
主营业务:
上海君实生物医药科技股份有限公司是一家主要从事创新驱动型生物制药业务的中国公司。该公司主要开发创新药物,并全球范围内提供临床研究商业化服务。该公司产品覆盖肿瘤免疫治疗、代谢类疾病、炎症或自身免疫性疾病及神经系统疾病等多个治疗领域。该公司的药品主要用于治疗黑色素瘤、鼻咽癌、食管癌、尿路上皮癌、恶性淋巴瘤等。该公司主要于国内及海外市场提供产品。
发行价格:
--
{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"君实生物","latestPrice":12.98,"timestamp":1721635736028,"preClose":12.68,"halted":0,"volume":419400,"delay":0,"floatShares":219295700,"shares":985689871,"eps":-2.4840324,"marketStatus":"已收盘","marketStatusCode":5,"change":0.3,"latestTime":"07-22 16:08:56","open":13,"high":13.26,"low":12.56,"amount":5450920,"amplitude":0.055205,"askPrice":12.98,"askSize":2000,"bidPrice":12.92,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-2.2075349266106623,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721698200000},"adr":0,"listingDate":1545580800000,"adjPreClose":12.68,"openAndCloseTimeList":[[1721611800000,1721620800000],[1721624400000,1721635200000]],"volumeRatio":0.582565,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物","latestPrice":32,"timestamp":1721631600000,"preClose":31.69,"halted":0,"volume":3346069,"delay":0,"premium":"-62.12"}},"requestUrl":"/m/hq/s/01877/wiki","defaultTab":"wiki","newsList":[{"id":"2452493098","title":"北向资金7月18日净买入君实生物-U25.58万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2452493098","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452493098?lang=zh_cn&edition=full","pubTime":"2024-07-19 09:30","pubTimestamp":1721352640,"startTime":"0","endTime":"0","summary":"7月18日, 北向资金增持君实生物-U25.58万股,连续3日增持。截止当日收盘,沪股通共持有君实生物-U1085.16万股,占流通股1.41%。沪股通增持金额前五个股分别为紫金矿业、韦尔股份、赤峰黄金、XD中金黄、长江电力。君实生物-U近5个交易日上涨1.60%,沪股通累计增持33.47万股;近20个交易日上涨10.53%,沪股通累计增持8.64万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407190935119f68688e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407190935119f68688e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1161","01877","BK1583"],"gpt_icon":0},{"id":"2452149806","title":"港股异动 | 君实生物(01877)涨超4% 特瑞普利单抗新适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2452149806","media":"智通财经网","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2452149806?lang=zh_cn&edition=full","pubTime":"2024-07-18 09:57","pubTimestamp":1721267862,"startTime":"0","endTime":"0","summary":"消息面上,君实生物公布,近日,公司收到国家药监局核准签发的《受理通知书》,特瑞普利单抗联合贝伐珠单抗用于不可切除或转移性肝细胞癌患者的一线治疗的新适应症上市申请获得受理。这是特瑞普利单抗在中国内地递交的第十一项上市申请。天风证券此前指出,公司营业收入增长主要来自商业化药品销售收入的增长,其中核心产品特瑞普利单抗贡献突出。2023 年,特瑞普利单抗销售收入9.19 亿元,同比增长约24.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152425.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1515","YANG","BK1583","BK0239","HSTECH","688180","BK1161","01877","HSCEI"],"gpt_icon":1},{"id":"2452111266","title":"智通港股早知道 | 两部门再出减税惠企大礼包 华为Pura 70系列手机爆火","url":"https://stock-news.laohu8.com/highlight/detail?id=2452111266","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452111266?lang=zh_cn&edition=full","pubTime":"2024-07-18 07:40","pubTimestamp":1721259616,"startTime":"0","endTime":"0","summary":"华为Pura 70系列手机爆火!出货量比P60系列增长125%7月17日,中国证券报·中证金牛座记者从华为内部人士获悉,自4月18日Pura70系列开启先锋计划销售以来,截至7月16日,华为Pura 70系列出货量比同期P60系列增长125%。增持后最新持股数目约为15.38亿股,持股比例为61.69%。华润博雅生物以自有资金18.2亿元收购GC集团持有的绿十字香港控股有限公司100%股权,从而间接收购境内血液制品主体绿十字(中国)生物制品有限公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01072","BK1205","BK1583","BK1171","BK1225","BK1515","BK1161","BK1594","BK1546","03898","IE0032431581.USD","BK1191","00512","BK1568","BK1565","BK1116","BK1147","07226","BK1522","HSTECH","01053","01877","HSCEI","YANG","01788"],"gpt_icon":0},{"id":"2452162091","title":"君实生物(01877.HK)特瑞普利单抗新适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2452162091","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452162091?lang=zh_cn&edition=full","pubTime":"2024-07-18 00:49","pubTimestamp":1721234940,"startTime":"0","endTime":"0","summary":"君实生物(01877.HK) 公布,收到国家药品监督管理局通知,特瑞普利单抗(商品名:拓益,产品代号:JS001)联合贝伐珠单抗用于不可切除或转移性肝细胞癌患者的一线治疗的新适应症上市申请获得受理。本次新适应症上市申请主要基于HEPATORCH研究,结果显示,特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌患者,相较于索拉非尼,可显著延长患者的无进展生存期和总生存期,同时改善客观缓解率和至疾病进展时间等次要终点。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-17 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1364411/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1583","BK1515","BK0239","01877","688180"],"gpt_icon":0},{"id":"2452516510","title":"港股公告掘金 | 时代电气预期上半年归母净利约15.07亿元 同比增长30.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452516510","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452516510?lang=zh_cn&edition=full","pubTime":"2024-07-17 22:59","pubTimestamp":1721228378,"startTime":"0","endTime":"0","summary":"【重大事项】宏华集团(00196)附属与中东客户签署合计金额超15亿元的智能钻机销售协议华润医药(03320)附属拟18.2亿元收购Green Cross HK的100%权益 并与GC Corp订立战略合作框架协议君实生物(01877):特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的新适应症上市申请获得受理【财报数据】金斯瑞生物科技(01548):CARVYKTI第二季度贸易销售净额约1.86亿","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152348.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688187","BK1576","BK1570","BK1583","BK1161","BK1191","HK0000306685.HKD","HSTECH","BK1141","HK0000306701.USD","01548","HK0000320264.USD","BK0279","03320","BK1565","IE0032431581.USD","HSCEI","HK0000320223.HKD","03898","YANG","01877","BK1515","BK1116","BK1171"],"gpt_icon":1},{"id":"2452156191","title":"君实生物(01877):特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的新适应症上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2452156191","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452156191?lang=zh_cn&edition=full","pubTime":"2024-07-17 20:33","pubTimestamp":1721219586,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物 公布,近日,公司收到国家药品监督管理局核准签发的《受理通知书》,特瑞普利单抗联合贝伐珠单抗用于不可切除或转移性肝细胞癌患者的一线治疗的新适应症上市申请获得受理。研究结果显示,特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌患者,相较于索拉非尼,可显著延长患者的 PFS 和 OS,同时改善客观缓解率和至疾病进展时间等次要终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","BK0239","688180","01877","BK1583"],"gpt_icon":0},{"id":"2452134000","title":"君实生物:特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的新适应症上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2452134000","media":"国际金融报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452134000?lang=zh_cn&edition=full","pubTime":"2024-07-17 18:43","pubTimestamp":1721213008,"startTime":"0","endTime":"0","summary":"君实生物公告,特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的新适应症上市申请获得受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240717184337af92c301&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240717184337af92c301&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK0239","688180"],"gpt_icon":0},{"id":"2451117953","title":"君实生物(01877)下跌5.13%,报12.58元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2451117953","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451117953?lang=zh_cn&edition=full","pubTime":"2024-07-16 14:28","pubTimestamp":1721111308,"startTime":"0","endTime":"0","summary":"7月16日,君实生物(01877)盘中下跌5.13%,截至14:28,报12.58元/股,成交937.54万元。上海君实生物医药科技股份有限公司主要业务是发现、开发和商业化创新疗法,特别是在肿瘤免疫疗法、自身免疫系统疾病、慢性代谢类疾病、神经系统疾病、感染类疾病等治疗方面。公司拥有卓越的创新药物发现能力、先进的生物技术研发、全产业链大规模生产技术和极具市场潜力的在研药品组合。截至2024年一季报,君实生物营业总收入3.81亿元、净利润-2.83亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/16142841591216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","01877","688180","BK1515","BK1583","BK1161"],"gpt_icon":0},{"id":"2451953474","title":"君实生物盘中异动 下午盘快速跳水5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2451953474","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451953474?lang=zh_cn&edition=full","pubTime":"2024-07-16 14:28","pubTimestamp":1721111305,"startTime":"0","endTime":"0","summary":"2024年07月16日下午盘14时28分,君实生物股票出现异动,股价快速跳水5.13%。截至发稿,该股报12.581港元/股,成交量72.4万股,换手率0.33%,振幅6.18%。君实生物股票所在的生物技术行业中,整体跌幅为0.12%。其相关个股中,维亚生物、亚盛医药-B、再鼎医药涨幅较大,振幅较大的相关个股有维亚生物、宜明昂科-B、圣诺医药-B,振幅分别为17.00%、16.14%、14.89%。药品批发,药品委托生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407161428259681d1fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407161428259681d1fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","01877","688180"],"gpt_icon":0},{"id":"2450370044","title":"君实生物07月12日获主力加仓239万元 环比增加696.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450370044","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450370044?lang=zh_cn&edition=full","pubTime":"2024-07-12 16:16","pubTimestamp":1720772190,"startTime":"0","endTime":"0","summary":"07月12日, 君实生物股价涨3.44%,报收13.24元,成交金额1417万元,换手率0.49%,振幅3.59%,量比1.61。君实生物今日主力资金净流入239万元,连续3日净流入,上一交易日主力净流入30万元,今日环比增加696.67%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为60.00%,平均涨幅为1.84%。该股近5个交易日上涨6.42%,主力资金累计净流入362万元;近20日主力资金累计净流入839万元,其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407121616529f3a6033&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407121616529f3a6033&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK1515","BK1161","BK1583"],"gpt_icon":0},{"id":"2450803833","title":"君实生物(01877)上涨5.13%,报13.12元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2450803833","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450803833?lang=zh_cn&edition=full","pubTime":"2024-07-11 10:50","pubTimestamp":1720666206,"startTime":"0","endTime":"0","summary":"7月11日,君实生物(01877)盘中上涨5.13%,截至10:50,报13.12元/股,成交572.59万元。上海君实生物医药科技股份有限公司主要业务是发现、开发和商业化创新疗法,特别是在肿瘤免疫疗法、自身免疫系统疾病、慢性代谢类疾病、神经系统疾病、感染类疾病等治疗方面。公司拥有卓越的创新药物发现能力、先进的生物技术研发、全产业链大规模生产技术和极具市场潜力的在研药品组合。截至2024年一季报,君实生物营业总收入3.81亿元、净利润-2.83亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/11105041505681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","BK1161","BK0239","01877","BK1515","688180"],"gpt_icon":0},{"id":"2450808999","title":"君实生物盘中异动 急速上涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450808999","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450808999?lang=zh_cn&edition=full","pubTime":"2024-07-11 10:49","pubTimestamp":1720666198,"startTime":"0","endTime":"0","summary":"2024年07月11日早盘10时49分,君实生物股票出现异动,股价急速上涨5.12%。截至发稿,该股报13.120港元/股,成交量44.38万股,换手率0.20%,振幅4.65%。君实生物股票所在的生物技术行业中,整体涨幅为1.58%。其相关个股中,北海康成-B、荣昌生物、盛禾生物-B涨幅较大,振幅较大的相关个股有北海康成-B、科伦博泰生物-B、盛禾生物-B,振幅分别为31.25%、19.37%、17.45%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407111049599681bdec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407111049599681bdec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK0239","688180"],"gpt_icon":0},{"id":"2450380335","title":"君实生物(01877)股价上升5.128%,现价港币$13.12","url":"https://stock-news.laohu8.com/highlight/detail?id=2450380335","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450380335?lang=zh_cn&edition=full","pubTime":"2024-07-11 10:49","pubTimestamp":1720666140,"startTime":"0","endTime":"0","summary":"[上升股]君实生物(01877) 股价在上午10:49比前收市价上升5.128%,现股价为港币$13.12。至目前为止,今日最高价为$13.12,而最低价为$12.54。总成交量为44.38万股,总成交金额为港币$572.586万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2407112881/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01877","BK1515","688180","BK0239","BK1583","BK1161"],"gpt_icon":0},{"id":"2450324870","title":"港股异动 | 生物医药股集体回暖 创新药重磅利好政策落地 下半年板块仍有多重催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2450324870","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450324870?lang=zh_cn&edition=full","pubTime":"2024-07-11 10:23","pubTimestamp":1720664601,"startTime":"0","endTime":"0","summary":"东吴证券表示,《全链条支持创新药发展实施方案》具体条款有望近期落地,叠加创新药板块处于历史相对底部位置,下半年有ESMO大会、WCLC大会、医保谈判、创新药出海预期等多重催化,创新药板块有望走强。西南证券指出,2024年,预计将有超30个国产创新药有望获批上市,以及众多优异临床数据披露,有望为公司业绩赋能,成为股价重要催化剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["YANG","BK1583","161726","BK1161","BK1515","BK1574","399441","06990","HK0000306685.HKD","BK1141","LU1969619763.USD","HK0000320264.USD","HK0000306701.USD","09995","01548","LU2328871848.SGD","06978","HSTECH","HSCEI","HK0000320223.HKD","07226","159992","BK1576","01877","LU0196878994.USD"],"gpt_icon":0},{"id":"2450864003","title":"君实生物(01877)全资子公司苏州众合生物医药科技通过欧盟 GMP 认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2450864003","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450864003?lang=zh_cn&edition=full","pubTime":"2024-07-10 18:15","pubTimestamp":1720606544,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物 公布,近日,公司全资子公司苏州众合生物医药科技有限公司收到爱尔兰健康产品监督管理局依据欧洲药品管理局相关法规颁发的《CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER》。本次系公司核心产品特瑞普利单抗注射液的相关生产设施首次通过欧盟成员国 GMP 认证。根据欧盟成员国之间的 GMP 互认制度,本次通过 GMP 认证表明本次接受认证的生产设施已符合欧盟 GMP 标准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1148749.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1583","BK0239","688180","BK1161","161726","01877","399441"],"gpt_icon":0},{"id":"2450865483","title":"君实生物(688180.SH):子公司通过欧盟GMP认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2450865483","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450865483?lang=zh_cn&edition=full","pubTime":"2024-07-10 17:14","pubTimestamp":1720602843,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物(688180.SH)发布公告,公司全资子公司苏州众合生物医药科技有限公司收到爱尔兰健康产品监督管理局依据欧洲药品管理局相关法规颁发的《药品GMP证书》。本次系公司核心产品特瑞普利单抗注射液的相关生产设施首次通过欧盟成员国GMP认证。根据欧盟成员国之间的GMP互认制度,本次通过GMP认证表明本次接受认证的生产设施已符合欧盟GMP标准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1148634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688180","BK1515","BK1583","BK0239","01877","BK1161"],"gpt_icon":0},{"id":"2450755075","title":"君实生物(01877.HK)WJ47156片临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2450755075","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450755075?lang=zh_cn&edition=full","pubTime":"2024-07-10 01:48","pubTimestamp":1720547280,"startTime":"0","endTime":"0","summary":"君实生物(01877.HK) 公布,收到国家药品监督管理局通知书,WJ47156片(项目代号JS125)的临床试验申请获得受理。JS125是靶向组蛋白去乙酰化酶抑制剂,由公司与微境生物医药科技(上海)合作开发,拟用于恶性肿瘤的治疗。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-09 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20200529130906781_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20200529130906781_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1362448/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0239","688180","BK1161","BK1141","01877","03347","BK1515","BK1576","BK1583"],"gpt_icon":0},{"id":"2450047443","title":"君实生物(01877):JS125 获得药物临床试验申请受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2450047443","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450047443?lang=zh_cn&edition=full","pubTime":"2024-07-09 21:18","pubTimestamp":1720531122,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物 公布,近日,公司收到国家药品监督管理局核准签发的《受理通知书》,WJ47156 片的临床试验申请获得受理。HDACs 具有多种亚型,JS125 可选择性对 HDAC1、HDAC2、HDAC3 产生抑制,并通过诱导细胞周期阻滞、抑制血管生成、调节免疫反应和促进癌症细胞衰老凋亡等来发挥抑制肿瘤作用,达到肿瘤治疗目的。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1148228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK0239","BK1141","688180","BK1583","BK1161","BK1515","BK1576","01877"],"gpt_icon":0},{"id":"2449744252","title":"港股异动 | 生物医药股全线回落 创新药重磅利好政策落地 机构称新环境下谈判难度增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2449744252","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449744252?lang=zh_cn&edition=full","pubTime":"2024-07-08 15:01","pubTimestamp":1720422060,"startTime":"0","endTime":"0","summary":"招银国际指出,预计医疗设备更新的政策将在全国陆续落地,将有效刺激相关需求释放。该行认为,随着支持政策落地、行业监管常态化进行,业绩复苏将带来行业估值修复。此外,2024年医保目录调整正式启动,新环境下谈判难度增加,预计2024年符合谈判资格的创新药将达到180个品种,我们预计平均降幅可能超过2023年。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146808.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","LU1969619763.USD","BK1515","BK1574","BK1161","161726","LU2045819591.USD","399441","LU0320764599.SGD","06978","LU0052750758.USD","03347","LU2125910500.SGD","LU2242644610.SGD","BK1141","BK1576","LU0708995583.HKD","LU1046422090.SGD","07226","02359","HSTECH","01877","HSCEI","YANG","09995","LU2328871848.SGD","159992"],"gpt_icon":0},{"id":"2449713882","title":"君实生物-U7月5日获北向资金加仓125.97万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2449713882","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449713882?lang=zh_cn&edition=full","pubTime":"2024-07-08 09:30","pubTimestamp":1720402234,"startTime":"0","endTime":"0","summary":"7月5日, 北向资金增持君实生物-U125.97万股。截止当日收盘,沪股通共持有君实生物-U1061.21万股,占流通股1.38%。沪股通增持金额前五个股分别为国投电力、中金黄金、中国核电、川投能源、中国石油。君实生物-U近5个交易日上涨3.27%,沪股通累计增持31.54万股;近20个交易日上涨4.53%,沪股通累计减持773.01万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240708093424958d28a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240708093424958d28a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1515","01877","BK1583"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0423},{"period":"1month","weight":0.0691},{"period":"3month","weight":0.3723},{"period":"6month","weight":-0.1501},{"period":"1year","weight":-0.4717},{"period":"ytd","weight":-0.3477}],"compareEarnings":[{"period":"1week","weight":-0.0479},{"period":"1month","weight":-0.0549},{"period":"3month","weight":0.0736},{"period":"6month","weight":0.1378},{"period":"1year","weight":-0.0798},{"period":"ytd","weight":0.0217}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海君实生物医药科技股份有限公司是一家主要从事创新驱动型生物制药业务的中国公司。该公司主要开发创新药物,并全球范围内提供临床研究商业化服务。该公司产品覆盖肿瘤免疫治疗、代谢类疾病、炎症或自身免疫性疾病及神经系统疾病等多个治疗领域。该公司的药品主要用于治疗黑色素瘤、鼻咽癌、食管癌、尿路上皮癌、恶性淋巴瘤等。该公司主要于国内及海外市场提供产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.122873},{"month":2,"riseRate":0.833333,"avgChangeRate":0.02917},{"month":3,"riseRate":0.666667,"avgChangeRate":0.049114},{"month":4,"riseRate":0.833333,"avgChangeRate":0.112597},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.034116},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.02585},{"month":7,"riseRate":0.5,"avgChangeRate":-0.049474},{"month":8,"riseRate":0,"avgChangeRate":-0.093613},{"month":9,"riseRate":0,"avgChangeRate":-0.097134},{"month":10,"riseRate":0.4,"avgChangeRate":0.053036},{"month":11,"riseRate":0.6,"avgChangeRate":0.067975},{"month":12,"riseRate":0.8,"avgChangeRate":0.175695}],"exchange":"SEHK","name":"君实生物","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,01877,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}